Navigation Links
Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
Date:12/17/2008

l be presented at an upcoming medical meeting, along with additional efficacy data from the 240 mg/day and lower dose groups. Final selection of the Phase 3 dose will be made following completion of data analyses.

"We are pleased to have reached another development milestone in our prostate cancer program by successfully completing enrollment in our Phase 1-2 clinical trial in castration-resistant prostate cancer patients with limited treatment options," said Lynn Seely, M.D., chief medical officer of Medivation. "We look forward to presenting additional data from this trial and to advancing this program into Phase 3 development in 2009, as we have previously guided."

About Prostate Cancer and MDV3100

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer. An estimated 186,320 new cases are expected to be diagnosed in 2008, and approximately 28,660 men are expected to die this year from the disease. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Overexpression of the androgen receptor is believed to contribute to the progression of castration-resistant prostate cancer. MDV3100 is a novel small-molecule androgen receptor antagonist that inhibits androgen receptor function by blocking nuclear translocation of the androgen receptor and DNA binding.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation entered into a global agreement with Pfizer Inc to de
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
7. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
8. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
9. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
10. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
11. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ) ... to Prepare Application Dossiers for Oversea Medical device ... report to their offering. The ... market of the most growth potentiality, which is ... and producers to penetrate such market. It is ...
(Date:5/22/2015)... , May 22, 2015 Today, ... central nervous system stimulant indicated for the treatment ... patients beginning Summer 2015. The ... received approval from the U.S. Food and Drug ... an extended-release formulation of methylphenidate capsule with an ...
(Date:5/22/2015)... , May 22, 2015 AcelRx Pharmaceuticals, ... focused on the development and commercialization of innovative therapies ... announced that interim chief executive officer Howie Rosen ... and chief financial officer Tim Morris will ... of the two presentations are as follows: ...
Breaking Medicine Technology:China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2
... Partners, Aesculap and Tornier, Conduct Clinical ... Evaluations of TephaFLEX(R) Suture Products, LEXINGTON, Mass., ... derived from a new class of polymers, announced today ... conducting initial,clinical evaluations of the Company,s new TephaFLEX(R) suture ...
... (Nasdaq: KOSN ) presented preclinical data on ... vitro and in vivo,activity as well as tolerability ... anticancer mechanism of action correlating inhibition,of the target ... cells,compared to normal cells. Data on Kosan,s NEIs ...
Cached Medicine Technology:Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers 2Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 2Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 3Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 4
(Date:5/24/2015)... 2015 Indiana Fiber Network, LLC (IFN), ... Telecom of America, Inc. (MTA) has selected IFN as ... Childs, IFN Enterprise Sales Manager, fiber route diversity and ... fiber transport provides MTA with the diverse fiber transport ... 1 Internet and voice carriers located at Henry Street ...
(Date:5/24/2015)... (PRWEB) May 24, 2015 ... System CEO - The students ... honored at the fourth annual A ... 15 at Geneva National in Lake ... ,     -Badger High School,         Jonathan Alfonso, ...
(Date:5/23/2015)... May 23, 2015 On Saturday, May 23, ... new playground for Branches Florida City exactly five years to ... space in 2010. , A large fire tore through the ... May 23, 2010 in the middle of the night as ... was later declared arson even though it is suspected that ...
(Date:5/23/2015)... 2015 Dr. David Benvenuti, an experienced plastic ... a new article to his website that takes ... Benvenuti explained in the fascinating blog, he has recently ... earlobes. , Known as “gauging,” the technique involves placing larger ... Benvenuti said will eventually stretch the holes out to incredible ...
(Date:5/23/2015)... 2015 On Wednesday, May 20, 2015, ... has been the target of a sophisticated cyberattack,” and ... company’s ongoing Information Technology (IT) security efforts in the ... The most notable attack on health insurers was reported ... nation’s second largest health insurer, revealed that they had ...
Breaking Medicine News(10 mins):Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4
... of Allergy and Infectious Diseases (NIAID), part of the ... to two programs that support research to better understand ... diseases, including those that may be introduced into a ... awarded to the Cooperative Centers for Translational Research on ...
... parents around the country are starting to face school ... for a school to shut down? A study led ... PhD of the Children,s Hospital Boston Informatics Program, in ... (Niigata, Japan), tapped a detailed set of Japanese data ...
... ... Change , ... D.C. (Vocus) November 4, 2009 -- Changes to the Earth’s land cover, climate, and ... and now represent the greatest public health challenge of the 21st century. The scale ...
... half of those with lung disease symptoms remain undiagnosed, experts ... Americans are aware of chronic obstructive pulmonary disease (COPD), but ... be treated, according to national survey results released this week ... Month in November. , COPD affects 20 percent of U.S. ...
... , ... Future-focused performance management system prepares hospital leaders for the changing health care environment. ... ... extreme financial challenges—payment reform, reimbursement changes and a shift of patient services to ...
... 4 In order to help millions of ... medical conditions, depression and obesity, the Neutraceutical Company, ... with the ability to address both issues safely ... Wellness brand, has clinically established a remarkable success ...
Cached Medicine News:Health News:NIAID announces new human immunology research awards to help fight emerging infectious diseases 2Health News:NIAID announces new human immunology research awards to help fight emerging infectious diseases 3Health News:When should flu trigger a school shutdown? 2Health News:When should flu trigger a school shutdown? 3Health News:Not What the Doctor Ordered: Rapid Environmental Change Threatens the Foundations of Human Health 2Health News:Not What the Doctor Ordered: Rapid Environmental Change Threatens the Foundations of Human Health 3Health News:Not What the Doctor Ordered: Rapid Environmental Change Threatens the Foundations of Human Health 4Health News:Americans Gaining Awareness of COPD: Survey 2Health News:Sg2 Announces Its INSIGHT System to Improve Hospitals' Clinical Performance and Bottom Line Results 2Health News:Sg2 Announces Its INSIGHT System to Improve Hospitals' Clinical Performance and Bottom Line Results 3Health News:New Product Launch - SAFFRENE Delivers Impressive Mood Elevation and Weight-loss Benefits 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: